BRAINTREE, Mass., April 27, 2015 /PRNewswire/ -- Haemonetics Corporation ( NYSE: HAE) announced today expanded roles for two executives. These changes are part of an ongoing plan to advance the Company's global leadership in blood management solutions and to execute on strategies to enhance shareholder value.
Kent Davies, who joined the Company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO. In this expanded role, Mr. Davies will have overall accountability for the Company's commercial, product development and product management focus across the entire portfolio and in all geographies.
Byron Selman, who joined the Company upon the acquisition of Pall Corporation's transfusion medicine business in 2012, is appointed to the position of President, Global Markets, reporting to Mr. Davies. Mr. Selman will oversee the Company's global commercial and market development efforts, with the exception of the Company's commercial Plasma business.
Mr. Concannon stated: "Haemonetics enters fiscal 2016 with good momentum, brought about by recent contract wins, new product innovations and launches, and a Comprehensive Blood Management Solutions (CBMS) offering that is gaining traction with customers. These two management promotions will enhance our execution efforts and strategic focus in all of our markets, while leveraging our strengths in product management and product development."
Haemonetics ( NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit the web site www.haemonetics.com.
FORWARD LOOKING STATEMENTS
This release contains forward-looking statements that involve risks and uncertainties, including the effects of disruption from the manufacturing transformation making it more difficult to maintain relationships with employees and timely deliver high quality products, unexpected expenses incurred during our Value Creation and Capture program, technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, demand for whole blood and blood components, product quality, market acceptance, regulatory uncertainties, including in the receipt or timing of regulatory approvals, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns including single-source tenders, the effect of industry consolidation as seen in the plasma and blood center markets, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission.
The foregoing list should not be construed as exhaustive.
Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements. Information set forth in this press release is current as of today and the Company undertakes no duty or obligation to update this information.
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
Alt. (781) 356-9613
SOURCE Haemonetics Corporation